公开(公告)号：US20240117057A1

公开(公告)日：2024-04-11

申请号：US18273680

申请日：2022-01-21

Applicant: Celldex Therapeutics, Inc.

Inventor： Joel Goldstein

IPC: C07K16/28 ,  A61P17/00

CPC classification number: C07K16/2866 ,  A61P17/00 ,  C07K2317/52 ,  C07K2317/76

Abstract: Provided herein are antibodies that immunospecifically bind to KIT, a receptor tyrosine kinase, and uses thereof. Also provided are polynucleotides and vectors encoding such antibodies, cells comprising such polynucleotides or vectors, and methods of making such antibodies.

公开(公告)号：US20240117028A1

公开(公告)日：2024-04-11

申请号：US18492150

申请日：2023-10-23

Applicant: Genzyme Corporation

Inventor： Huawei QIU ,  Julie BIRD

IPC: C07K16/22 ,  A61K39/395 ,  C12N15/11

CPC classification number: C07K16/22 ,  A61K39/3955 ,  C12N15/11 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: A modified IgG antibody binds and neutralizes TGFβl selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.

公开(公告)号：US11945880B2

公开(公告)日：2024-04-02

申请号：US17542342

申请日：2021-12-03

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal ,  Sung-Hyung Lee

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K16/468 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/40 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention is directed to novel heterodimeric antibodies.

公开(公告)号：US20240101643A1

公开(公告)日：2024-03-28

申请号：US18318487

申请日：2023-05-16

Applicant: Hoffmann-La Roche Inc.

Inventor： Roberto FALKENSTEIN ,  Heiko WALCH ,  Sebastian MALIK ,  Marco THOMANN ,  Matthias FREIHERR VON ROMAN ,  Ingrid GRUNERT ,  Roland DORN ,  Michael HINGAR

IPC: C07K16/00 ,  C07K1/22 ,  C12P21/00

CPC classification number: C07K16/00 ,  C07K1/22 ,  C12P21/005 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55

Abstract: Herein is reported a method for producing an antibody comprising the steps of forming an antibody-antibody light chain affinity ligand complex, wherein the antibody light chain affinity ligand is immobilized on a solid phase, by applying a solution comprising the antibody to the immobilized antibody light chain affinity ligand, and incubating the complex formed in the previous step with one or more enzymes to modify the glycosylation of the antibody, thereby producing the antibody.

公开(公告)号：US11939391B2

公开(公告)日：2024-03-26

申请号：US17542948

申请日：2021-12-06

Applicant: MedAbome, Inc.

Inventor： Mason Lu ,  Qinhong Ma

IPC: C07K16/28 ,  A61K35/17

CPC classification number: C07K16/2896 ,  A61K35/17 ,  C07K16/2863 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/03

Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing transferrin receptor 1 (TfR1) and its variants on the cell surface, including but not limited to AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain and heavy chain variable regions of an anti-TfR1 monoclonal antibody (mAb), MAb11-22.1, which, is highly specific for tumor cells and in an ADC form, can functionally inhibit the proliferation of several human cancer cell lines and the growth of AML cell line-derived xenograft tumors in mouse models.

公开(公告)号：US20240092890A1

公开(公告)日：2024-03-21

申请号：US18041818

申请日：2021-08-26

Applicant: JUNTENDO EDUCATIONAL FOUNDATION ,  MEIJI SEIKA PHARMA CO., LTD.

Inventor： Norio KOMATSU ,  Marito ARAKI ,  Yoshihiko KIHARA ,  Yoji ISHIDA ,  Koichi KITAMURA ,  Takayoshi FUKUSHIMA ,  Kaori YASUI

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/28 ,  C07K16/2809 ,  G01N33/57492 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/92

Abstract: A bispecific antibody including a first domain which specifically binds to a mutant calreticulin protein and a second domain which specifically binds to a CD3 antigen. A pharmaceutical composition including the bispecific antibody or a functional fragment thereof. A diagnostic method for a myeloproliferative neoplasm, including detecting a polypeptide in a biological sample with the bispecific antibody.

公开(公告)号：US11932704B2

公开(公告)日：2024-03-19

申请号：US17515227

申请日：2021-10-29

Applicant: Sanofi

Inventor： Zhi-Yong Yang ,  Gary J. Nabel ,  Lan Wu ,  Edward Seung ,  Ronnie Wei ,  Jochen Beninga ,  Ercole Rao ,  Wulf Dirk Leuschner ,  Christian Beil ,  Christian Lange ,  Carsten Corvey

IPC: C07K16/46 ,  A61K39/395 ,  A61K45/06 ,  C07K1/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K1/22 ,  C07K16/241 ,  C07K16/244 ,  C07K16/247 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/64 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

公开(公告)号：US20240084001A1

公开(公告)日：2024-03-14

申请号：US18063477

申请日：2022-12-08

Applicant: LamKap Bio beta Ltd.

Inventor： Vanessa BUATOIS ,  Sara MAJOCCHI ,  Klaus STREIN

IPC: C07K16/28 ,  C07K16/30 ,  C12N15/85

CPC classification number: C07K16/2803 ,  C07K16/2809 ,  C07K16/3007 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.

公开(公告)号：US20240076392A1

公开(公告)日：2024-03-07

申请号：US18261145

申请日：2022-02-17

Applicant: IGM Biosciences, Inc.

Inventor： Paul R. HINTON ,  Manal AMOURY

IPC: C07K16/28 ,  A61P35/02

CPC classification number: C07K16/2866 ,  A61P35/02 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/73 ,  C07K2317/92

Abstract: This disclosure provides an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD123. Also provided are polynucleotides encoding the antibody or antigen-binding fragment or derivative thereof and vectors and host cell comprising said polynucleotides. This disclosure further provides methods for producing and/or using an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD123.

公开(公告)号：US11919964B2

公开(公告)日：2024-03-05

申请号：US17005202

申请日：2020-08-27

Applicant: AMGEN INC.

Inventor： Gunasekaran Kannan ,  Ling Liu ,  Edward J. Belouski ,  Cen Xu

IPC: C07K16/28 ,  C07K16/18

CPC classification number: C07K16/2869 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.